Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3684
Predicate | Object |
---|---|
rdf:type | |
rdfs:label |
LAMICTAL (Tablet)
|
dailymed-instance:dosage |
Epilepsy:<br/>Adjunctive Use: LAMICTAL is indicated as adjunctive therapy for
partial seizures, the generalized seizures of Lennox-Gastaut syndrome,
and primary generalized tonic-clonic seizures in adult and pediatric
patients (���2 years of age).<br/>Monotherapy Use: LAMICTAL is indicated for conversion to monotherapy
in adults with partial seizures who are receiving treatment with carbamazepine,
phenytoin, phenobarbital, primidone, or valproate as the single AED. Safety and effectiveness
of LAMICTAL have not been established (1) as initial monotherapy,
(2) for conversion to monotherapy from AEDs other than carbamazepine,
phenytoin, phenobarbital, primidone, or valproate, or (3) for simultaneous
conversion to monotherapy from 2 or more concomitant AEDs.<br/>Bipolar Disorder: LAMICTAL is indicated
for the maintenance treatment of Bipolar I Disorder to delay the time
to occurrence of mood episodes (depression, mania, hypomania, mixed
episodes) in patients treated for acute mood episodes with standard
therapy. The effectiveness of LAMICTAL in the acute treatment of mood
episodes has not been established.<br/>General Dosing Considerations for Epilepsy and Bipolar Disorder
Patients: The risk of nonserious rash is increased when the
recommended initial dose and/or the rate of dose escalation of LAMICTAL
is exceeded. There are suggestions, yet to be proven, that the risk
of severe, potentially life-threatening rash may be increased by (1) coadministration
of LAMICTAL with valproate, (2) exceeding the recommended initial
dose of LAMICTAL, or (3) exceeding the recommended dose escalation
for LAMICTAL. However, caseshave been reported in the absence of
these factors (see BOX WARNING). Therefore, it is important that the
dosing recommendations be followed closely. It is recommended that LAMICTAL not be restarted in patients
who discontinued due to rash associated with prior treatment with
LAMICTAL, unless the potential benefits clearly outweigh the risks.
If the decision is made to restart a patient who has discontinued
LAMICTAL, the need to restart with the initial dosing recommendations
should beassessed. The greater the interval of time since the previous
dose, the greater consideration should be given to restarting with
the initial dosing recommendations. If a patient has discontinued
LAMICTAL for a period of more than 5 half-lives, it is recommended
that initial dosing recommendations and guidelines be followed.<br/>LAMICTAL Added to Drugs Known to Induce or Inhibit Glucuronidation: Drugs other than
those listed in PRECAUTIONS: Drug Interactions have not been systematically
evaluated in combination with LAMICTAL. Since lamotrigine is metabolized
predominantly by glucuronic acid conjugation, drugs that are known
to induce or inhibit glucuronidation may affect the apparent clearance
of lamotrigine and doses of LAMICTAL may require adjustment based
on clinical response.<br/>Target Plasma Levels for Patients With Epilepsy or Bipolar
Disorder: A therapeutic plasma concentration range has not
been established for lamotrigine. Dosing of LAMICTAL should be based
on therapeutic response. The half-life
of LAMICTAL is affected by other concomitant medications (see CLINICAL
PHARMACOLOGY: Pharmacokinetics and Drug Metabolism). See also DOSAGE AND ADMINISTRATION: Special Populations.<br/>Special Populations:<br/>Women and Oral Contraceptives:<br/>Adjustments to the Maintenance Dose of LAMICTAL: (1) Taking Estrogen-Containing
Oral Contraceptives: For women not taking carbamazepine,
phenytoin, phenobarbital, primidone, or rifampin, the maintenance
dose of LAMICTAL will in most cases need to be increased by as much
as 2���fold over the recommended target maintenance dose, in
order to maintain a consistent lamotrigine plasma level (see PRECAUTIONS:
Drug Interactions). (2) Starting
Estrogen-Containing Oral Contraceptives:In women taking
a stable dose of LAMICTAL and not taking carbamazepine, phenytoin,
phenobarbital, primidone, or rifampin, the maintenance dose will in
most cases need to be increased by as much as 2���fold, in order
to maintain a consistent lamotrigine plasma level. The dose increases
should begin at the same time that the oral contraceptive is introduced
and continue, based on clinical response, no more rapidly than 50
to 100 mg/day every week. Dose increases should not exceed the recommended
rate unless lamotrigine plasma levels or clinical response support
larger increases (see Table 11, column 2). Gradual transient increases
in lamotrigine plasma levels may occur during the week of inactive
hormonal preparation (���pill-free���week), and these increases
will be greater if dose increases are made in the days before or during
the week of inactive hormonal preparation. Increased lamotrigine plasma
levels could result in additional adverse events, such as dizziness,
ataxia, and diplopia (see PRECAUTIONS: Drug Interactions). If adverse
events attributable to LAMICTAL consistently occur during the���pill-free���week, dose adjustments to the overall maintenance dose may be necessary.
Dose adjustments limited to the���pill-free���week are
not recommended. For women taking LAMICTAL in addition to carbamazepine,
phenytoin, phenobarbital, primidone, or rifampin, no adjustment should
be necessary to the dose of LAMICTAL. (3) Stopping Estrogen-Containing Oral Contraceptives: For women not taking carbamazepine, phenytoin, phenobarbital, primidone,
or rifampin, the maintenance dose of LAMICTAL will in most cases need
to be decreased by as much as 50%, in order to maintain a consistent
lamotrigine plasma level. The decrease in the dose of LAMICTAL should
not exceed 25% of the total daily dose per week over a 2���week
period, unless clinical response or lamotrigine plasma levels indicate
otherwise (see PRECAUTIONS: Drug Interactions). For women taking LAMICTAL
in addition to carbamazepine, phenytoin, phenobarbital, primidone,
or rifampin, no adjustment to the dose of LAMICTAL should be necessary.<br/>Women and Other Hormonal Contraceptive Preparations or Hormone
Replacement Therapy: The effect of other hormonal contraceptive preparations
or hormone replacement therapy on the pharmacokinetics of lamotrigine
has not been systematically evaluated. It has been reported that ethinylestradiol,
not progestogens, increased the clearance of lamotrigine up to 2���fold,
and the progestin only pills had no effect on lamotrigine plasma levels.
Therefore, adjustments to the dosage of LAMICTAL in the presence of
progestogens alone will likely not be needed.<br/>Patients With Hepatic Impairment: Experience in patients with hepatic impairment is
limited. Based on a clinical pharmacology study in 24 patients with
mild, moderate, and severe liver dysfunction (see CLINICAL PHARMACOLOGY),
the following general recommendations can be made. No dosage adjustment
is needed in patients with mild liver impairment. Initial, escalation,
and maintenance doses should generally be reduced by approximately
25% in patients with moderate and severe liver impairment without
ascites and 50% in patients with severe liver impairment with ascites.
Escalation and maintenance doses may be adjusted according to clinical
response.<br/>Patients With Renal Functional Impairment: Initial doses of LAMICTAL should be based on patients'
AED regimen (see above); reduced maintenance doses may be effective
for patients with significant renal functional impairment (see CLINICAL
PHARMACOLOGY). Few patients with severe renal impairment have been
evaluated during chronic treatment with LAMICTAL. Because there is
inadequate experience in this population, LAMICTAL should be used
with cautionin these patients.<br/>Epilepsy:<br/>Adjunctive Therapy With LAMICTAL for Epilepsy: This
section provides specific dosing recommendations for patients 2 to
12 years of age and patients greater than 12 years of age.
Within each of these age-groups, specific dosing recommendations are
provided depending upon concomitant AED (Table 9 for patients 2 to
12 years of age and Table 11 for patients greater than 12 years
of age). A weight-based dosing guide for pediatric patients on concomitant
valproate is provided in Table 10.<br/>Conversion From Adjunctive Therapy With Carbamazepine, Phenytoin,
Phenobarbital, Primidone, or Valproate as the Single AED to Monotherapy
With LAMICTAL in Patients���16 Years of Age With Epilepsy: The goal of the transition regimen is to effect
the conversion to monotherapy with LAMICTAL under conditions that
ensure adequate seizure control while mitigating the risk of serious
rash associated with the rapid titration of LAMICTAL. The recommended maintenance dose of LAMICTAL as monotherapy is
500 mg/day given in 2 divided doses. To
avoid an increased risk of rash, the recommended initial dose and
subsequent dose escalations of LAMICTAL should not be exceeded (see
BOX WARNING).<br/>Conversion from Adjunctive Therapy With Antiepileptic Drugs
Other Than Carbamazepine, Phenytoin, Phenobarbital, Primidone, or
Valproate to Monotherapy With LAMICTAL: No specific dosing guidelines can be provided for
conversion to monotherapy with LAMICTAL with AEDs other than carbamazepine,
phenobarbital, phenytoin, primidone, or valproate.<br/>Usual Maintenance Dose for Epilepsy: The usual maintenance doses identified in Tables
9-11 are derived from dosing regimens employed in the placebo-controlled
adjunctive studies in which the efficacy of LAMICTAL was established.
In patients receiving multidrug regimens employing carbamazepine,
phenytoin, phenobarbital, or primidone without
valproate, maintenance doses of adjunctive LAMICTAL as high
as 700 mg/day have been used. In patients receiving valproate alone, maintenance doses of adjunctive
LAMICTAL as high as 200 mg/day have been used. The advantage
of using doses above those recommended in Tables 9-12 has not been
established in controlled trials.<br/>Discontinuation Strategy for Patients With Epilepsy: For patients receiving LAMICTAL in combination with
other AEDs, a reevaluation of all AEDs in the regimen should be considered
if a change in seizure control or an appearance or worsening of adverse
experiences is observed. If a decision
is made to discontinue therapy with LAMICTAL, a step-wise reduction
of dose over at least 2 weeks (approximately 50% per week) is
recommended unless safety concerns require a more rapid withdrawal
(see PRECAUTIONS). Discontinuing carbamazepine, phenytoin, phenobarbital, or primidone
should prolong the half-life of lamotrigine; discontinuing valproate
should shorten the half-life of lamotrigine.<br/>Bipolar Disorder: The goal of maintenance treatment with LAMICTAL
is to delay the time to occurrence of mood episodes (depression, mania,
hypomania, mixed episodes) in patients treated for acute mood episodes
with standard therapy. The target dose of LAMICTAL is 200 mg/day
(100 mg/day in patients taking valproate, which decreases the
apparent clearance of lamotrigine, and 400 mg/day in patients
not taking valproate and taking either carbamazepine, phenytoin, phenobarbital,
primidone, or rifampin, which increase the apparent clearance of lamotrigine).
In the clinical trials, doses up to 400 mg/day as monotherapy
were evaluated, however, no additional benefit was seen at 400 mg/day
compared to 200 mg/day (see CLINICAL STUDIES: Bipolar Disorder).
Accordingly, doses above 200 mg/day are not recommended. Treatment
with LAMICTAL is introduced, based on concurrent medications, according
to the regimen outlined in Table 13. If other psychotropic medications
are withdrawn following stabilization, the doseof LAMICTAL should
be adjusted. For patients discontinuing valproate, the dose of LAMICTAL
should be doubled over a 2-week period in equal weekly increments
(see Table 14). For patients discontinuing carbamazepine, phenytoin,
phenobarbital, primidone, or rifampin, the dose of LAMICTAL should
remain constant for the first week and then should be decreased by
half over a 2-week period in equal weekly decrements (see Table 14).
The dose of LAMICTAL may then be further adjusted to the target dose
(200 mg) as clinically indicated. Dosage adjustments
will be necessary in most patients who start or stop estrogen-containing
oral contraceptives while taking LAMICTAL (see DOSAGE AND ADMINISTRATION:
Special Populations: Women and Oral Contraceptives: Adjustments to
the Maintenance Dose of LAMICTAL). If other
drugs are subsequently introduced, the dose of LAMICTAL may need to
be adjusted. In particular, the introduction of valproate requires
reduction in the dose of LAMICTAL (see CLINICAL PHARMACOLOGY: Drug
Interactions). To avoid an increased risk
of rash, the recommended initial dose and subsequent dose escalations
of LAMICTAL should not be exceeded (see BOX WARNING). *See CLINICAL PHARMACOLOGY:
Drug Interactions and PRECAUTIONS: Drug Interactions for a description
of known drug interactions. ���Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin
have been shown to increase the apparent clearance of lamotrigine. ���Valproate has been shown
to decrease the apparent clearance of lamotrigine. *See CLINICAL PHARMACOLOGY:
Drug Interactions and PRECAUTIONS: Drug Interactions for a description
of known drug interactions. ���Carbamazepine, phenytoin, phenobarbital, primidone, and rifampin
have been shown to increase the apparent clearance of lamotrigine. ���Valproate has been shown
to decrease the apparent clearance of lamotrigine. There is no body of evidence available to answer the question
of how long the patient should remain on LAMICTAL therapy. Systematic
evaluation of the efficacy of LAMICTAL in patients with either depression
or mania who responded to standard therapy during an acute 8 to 16
week treatment phase and were then randomized to LAMICTAL or placebo
for up to 76 weeks of observation for affective relapse demonstrated
a benefit of such maintenance treatment (see CLINICAL STUDIES: Bipolar
Disorder). Nevertheless, patients should be periodically reassessed
to determine the need for maintenance treatment.<br/>Discontinuation Strategy in Bipolar Disorder: As with other AEDs, LAMICTAL should not be abruptly
discontinued. In the controlled clinical trials, there was no increase
in the incidence, type, or severity of adverse experiences following
abrupt termination of LAMICTAL. In clinical trials in patients with
bipolar disorder, 2 patients experienced seizures shortly after abrupt
withdrawal of LAMICTAL.However, there were confounding factors that
may have contributed to the occurrence of seizures in these bipolar
patients. Discontinuation of LAMICTAL should involve a step-wise reduction
of dose over at least 2 weeks (approximately 50% per week) unless
safety concerns require a more rapid withdrawal.<br/>Administration of LAMICTAL Chewable Dispersible Tablets: LAMICTAL Chewable Dispersible Tablets may be swallowed
whole, chewed, or dispersed in water or diluted fruit juice. If the
tablets are chewed, consume a small amount of water or diluted fruit
juice to aid in swallowing. To disperse
LAMICTAL Chewable Dispersible Tablets, add the tablets to a small
amount of liquid (1 teaspoon, or enough to cover the medication).
Approximately 1 minute later, when the tablets are completely
dispersed, swirl the solution and consume the entire quantity immediately. No attempt should be made to administer partial
quantities of the dispersed tablets.
|
dailymed-instance:descripti... |
LAMICTAL (lamotrigine), an antiepileptic drug
(AED) of the phenyltriazine class, is chemically unrelated to existing
antiepileptic drugs. Its chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-as -triazine, its molecular formula
is CHNCl, and its
molecular weight is 256.09. Lamotrigine is a white to pale cream-colored
powder and has a pKof 5.7. Lamotrigine is very slightly
soluble in water (0.17 mg/mL at 25��C) and slightly soluble
in 0.1 M HCl (4.1 mg/mL at 25��C). The structural formula
is: LAMICTAL Tablets are supplied for oral administration as 25-mg
(white), 100-mg (peach), 150-mg (cream), and 200-mg (blue) tablets.
Each tablet contains the labeled amount of lamotrigine and the following
inactive ingredients: lactose; magnesium stearate; microcrystalline
cellulose; povidone; sodium starch glycolate; FD&C Yellow No.
6 Lake (100-mg tablet only); ferric oxide, yellow (150-mg tablet only);
and FD&C Blue No. 2 Lake (200-mg tablet only). LAMICTAL Chewable Dispersible Tablets are supplied for oral administration.
The tablets contain 2 mg (white), 5 mg (white), or 25 mg
(white) of lamotrigine and the following inactive ingredients: blackcurrant
flavor, calcium carbonate, low-substituted hydroxypropylcellulose,
magnesium aluminum silicate, magnesium stearate, povidone, saccharin
sodium, and sodium starch glycolate.
|
dailymed-instance:clinicalP... |
Mechanism of Action: The precise mechanism(s) by which lamotrigine exerts
its anticonvulsant action are unknown. In animal models designed to
detect anticonvulsant activity, lamotrigine was effective in preventing
seizure spread in the maximum electroshock (MES) and pentylenetetrazol
(scMet) tests, and prevented seizures in the visually and electrically
evoked after-discharge (EEAD) tests for antiepileptic activity. LAMICTAL
also displayed inhibitory properties in the kindling model in ratsboth during kindling development and in the fully kindled state. The
relevance of these models to human epilepsy, however, is not known. One proposed mechanism of action of LAMICTAL, the
relevance of which remains to be established in humans, involves an
effect on sodium channels. In vitro pharmacological studies suggest
that lamotrigine inhibits voltage-sensitive sodium channels, thereby
stabilizing neuronal membranes and consequently modulating presynaptic
transmitter release of excitatory amino acids (e.g., glutamate and
aspartate). The mechanisms by which lamotrigine
exerts its therapeutic action in Bipolar Disorder have not been established.<br/>Pharmacological Properties: Although the relevance for human use is unknown,
the following data characterize the performance of LAMICTAL in receptor
binding assays. Lamotrigine had a weak inhibitory effect on the serotonin
5-HTreceptor (IC= 18��M).
It does not exhibit high affinity binding (IC>100��M)
to the following neurotransmitter receptors: adenosine Aand A; adrenergic��,��, and��; dopamine Dand D;��-aminobutyric
acid (GABA) A and B; histamine H; kappa opioid; muscarinic
acetylcholine; and serotonin 5-HT. Studies have failed
to detect an effect of lamotrigine on dihydropyridine-sensitive calcium
channels. It had weak effects at sigma opioid receptors (IC= 145��M). Lamotrigine did not inhibit the uptake
of norepinephrine, dopamine, or serotonin, (IC>200��M)
when tested in rat synaptosomes and/or human platelets in vitro.<br/>Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated
Activity: Lamotrigine did not inhibit N-methyl d-aspartate
(NMDA)-induced depolarizations in rat cortical slices or NMDA-induced
cyclic GMP formation in immature rat cerebellum, nor did lamotrigine
displace compounds that are either competitive or noncompetitive ligands
at this glutamate receptor complex (CNQX, CGS, TCHP). The ICfor lamotrigine effects on NMDA-induced currents (in the presence
of 3��M of glycine) in cultured hippocampal neurons exceeded
100��M.<br/>Folate Metabolism: In vitro, lamotrigine was shown to be an inhibitor
of dihydrofolate reductase, the enzyme that catalyzes the reduction
of dihydrofolate to tetrahydrofolate. Inhibition of this enzyme may
interfere with the biosynthesis of nucleic acids and proteins. When
oral daily doses of lamotrigine were given to pregnant rats during
organogenesis, fetal, placental, and maternal folate concentrations
were reduced. Significantly reduced concentrations of folate are associated
with teratogenesis (see PRECAUTIONS: Pregnancy). Folate concentrations
were also reduced in male rats given repeated oral doses of lamotrigine.
Reduced concentrations were partially returned to normal when supplemented
with folinic acid.<br/>Accumulation in Kidneys: Lamotrigine was found to accumulate in the kidney
of the male rat, causing chronic progressive nephrosis, necrosis,
and mineralization. These findings are attributed to��-2 microglobulin,
a species- and sex-specific protein that has not been detected in
humans or other animal species.<br/>Melanin Binding: Lamotrigine
binds to melanin-containing tissues, e.g., in the eye and pigmented
skin. It has been found in the uveal tract up to 52 weeks after
a single dose in rodents.<br/>Cardiovascular: In dogs, lamotrigine
is extensively metabolized to a 2-N-methyl metabolite. This metabolite
causes dose-dependent prolongations of the PR interval, widening of
the QRS complex, and, at higher doses, complete AV conduction block.
Similar cardiovascular effects are not anticipated in humans because
only trace amounts of the 2-N-methyl metabolite (<0.6% of lamotrigine
dose) have been found in human urine (see Drug Disposition). However,
it is conceivable that plasma concentrations of this metabolite could
be increased in patients with a reduced capacity to glucuronidate
lamotrigine (e.g., in patients with liver disease).<br/>Pharmacokinetics and Drug Metabolism: The pharmacokinetics of lamotrigine have been studied
in patients with epilepsy, healthy young and elderly volunteers, and
volunteers with chronic renal failure. Lamotrigine pharmacokinetic
parameters for adult and pediatric patients and healthy normal volunteers
are summarized in Tables 1 and 2. *The majority of parameter
means determined in each study had coefficients of variation between
20% and 40% for half-life and Cl/F and between 30% and 70% for T. The overall mean values were calculated from individual
study means that were weighted based on the number of volunteers/patients
in each study. The numbers in parentheses below each parameter mean
represent the range of individual volunteer/patient values across
studies. Carbamazepine, phenobarbital, phenytoin, and primidone have been
shown to increase the apparent clearance of lamotrigine. Estrogen-containing
oral contraceptives and rifampin have also been shown to increase
the apparent clearance of lamotrigine (see CLINICAL PHARMACOLOGY:
Drug Interactions and PRECAUTIONS: Drug Interactions).<br/>Absorption: Lamotrigine is rapidly and completely absorbed after
oral administration with negligible first-pass metabolism (absolute
bioavailability is 98%). The bioavailability is not affected by food.
Peak plasma concentrations occur anywhere from 1.4 to 4.8 hours
following drug administration. The lamotrigine chewable/dispersible
tablets were found to be equivalent, whether they were administered
as dispersed in water, chewed and swallowed, or swallowed as whole,
to the lamotrigine compressed tablets in terms of rate and extent
of absorption.<br/>Distribution: Estimates of the mean apparent volume of distribution
(Vd/F) of lamotrigine following oral administration ranged from 0.9
to 1.3 L/kg. Vd/F is independent of dose and is similar following
single and multiple doses in both patients with epilepsy and in healthy
volunteers.<br/>Protein Binding: Data from in vitro studies indicate that lamotrigine
is approximately 55% bound to human plasma proteins at plasma lamotrigine
concentrations from 1 to 10 mcg/mL (10 mcg/mL is 4 to 6
times the trough plasma concentration observed in the controlled efficacy
trials). Because lamotrigine is not highly bound to plasma proteins,
clinically significant interactions with other drugs through competition
for protein binding sites are unlikely. The binding of lamotrigine
to plasma proteins did not change in thepresence of therapeutic concentrations
of phenytoin, phenobarbital, or valproate. Lamotrigine did not displace
other AEDs (carbamazepine, phenytoin, phenobarbital) from protein
binding sites.<br/>Drug Disposition: Lamotrigine is metabolized predominantly by glucuronic
acid conjugation; the major metabolite is an inactive 2-N-glucuronide
conjugate. After oral administration of 240 mg ofC-lamotrigine (15��Ci) to 6 healthy volunteers, 94% was
recovered in the urine and 2% was recovered in the feces. The radioactivity
in the urine consisted of unchanged lamotrigine (10%), the 2-N-glucuronide
(76%), a 5-N-glucuronide (10%), a 2-N-methyl metabolite (0.14%), and
other unidentified minor metabolites (4%).<br/>Drug Interactions: The apparent clearance
of lamotrigine is affected by the coadministration of certain medications. Because lamotrigine is metabolized predominantly by glucuronic acid
conjugation, drugs that induce or inhibit glucuronidation may affect
the apparent clearance of lamotrigine. Carbamazepine,
phenytoin, phenobarbital, and primidone have been shown to increase
the apparent clearance of lamotrigine (see DOSAGE AND ADMINISTRATION
and PRECAUTIONS: Drug Interactions). Most clinical experience is derived
from patients taking these AEDs. Estrogen-containing
oral contraceptives and rifampin have also been shown to increase
the apparent clearance of lamotrigine (see PRECAUTIONS: Drug Interactions). Valproate decreases the
apparent clearance of lamotrigine (i.e., more than doubles the elimination
half-life of lamotrigine), whether given with or without carbamazepine,
phenytoin, phenobarbital, or primidone. Accordingly, if
lamotrigine is to be administered to a patient receiving valproate,
lamotrigine must be given at a reduced dosage, of no more than half
the dose used in patients not receiving valproate, even in the presence
of drugs that increase the apparent clearance of lamotrigine (see
DOSAGE AND ADMINISTRATION and PRECAUTIONS: Drug Interactions). The following drugs were shown not to increase the
apparent clearance of lamotrigine: felbamate, gabapentin, levetiracetam,
oxcarbazepine, pregabalin, and topiramate. Zonisamide does not appear
to change the pharmacokinetic profile of lamotrigine (see PRECAUTIONS:
Drug Interactions). In vitro inhibition
experiments indicated that the formation of the primary metabolite
of lamotrigine, the 2-N-glucuronide, was not significantly affected
by co-incubation with clozapine, fluoxetine, phenelzine, risperidone,
sertraline, or trazodone, and was minimally affected by co-incubation
with amitriptyline, bupropion, clonazepam, haloperidol, or lorazepam.
In addition, bufuralol metabolism data from human liver microsomes
suggested that lamotrigine does not inhibit the metabolism of drugs
eliminated predominantly by CYP2D6. LAMICTAL
has no effects on the pharmacokinetics of lithium (see PRECAUTIONS:
Drug Interactions). The pharmacokinetics
of LAMICTAL were not changed by coadministration of bupropion (see
PRECAUTIONS: Drug Interactions). Coadministration
of olanzapine did not have a clinically relevant effect on LAMICTAL
pharmacokinetics (see PRECAUTIONS: Drug Interactions).<br/>Enzyme Induction: The effects of lamotrigine on the induction of specific
families of mixed-function oxidase isozymes have not been systematically
evaluated. Following multiple administrations
(150 mg twice daily) to normal volunteers taking no other medications,
lamotrigine induced its own metabolism, resulting in a 25% decrease
in tand a 37% increase in Cl/F at steady state compared
to values obtained in the same volunteers following a single dose.
Evidence gathered from other sources suggests that self-induction
by LAMICTAL may not occur when LAMICTAL is given as adjunctive therapy
in patients receiving carbamazepine, phenytoin, phenobarbital, primidone,
or rifampin.<br/>Dose Proportionality: In healthy volunteers not receiving any other medications
and given single doses, the plasma concentrations of lamotrigine increased
in direct proportion to the dose administered over the range of 50
to 400 mg. In 2 small studies (n = 7 and 8) of patients
with epilepsy who were maintained on other AEDs, there also was a
linear relationship between dose and lamotrigine plasma concentrations
at steady state following doses of 50 to 350 mg twice daily.<br/>Elimination: (see Table 1).<br/>Special Populations:<br/>Age:<br/>Gender: The clearance of lamotrigine is not affected by
gender. However, during dose escalation of LAMICTAL in one clinical
trial in patients with epilepsy on a stable dose of valproate (n = 77),
mean trough lamotrigine concentrations, unadjusted for weight, were
24% to 45% higher (0.3 to 1.7 mcg/mL) in females than in males.<br/>Race: The apparent oral clearance of lamotrigine was 25%
lower in non-Caucasians than Caucasians.
|
dailymed-instance:activeIng... | |
dailymed-instance:contraind... |
LAMICTAL is contraindicated
in patients who have demonstrated hypersensitivity to the drug or
its ingredients.
|
dailymed-instance:supply |
LAMICTAL Tablets, 25-mg White, scored, shield-shaped tablets debossed
with "LAMICTAL" and "25", bottles of 100 (NDC 0173-0633-02). Store at 25��C (77��F);
excursions permitted to 15-30��C (59-86��F) [see USP Controlled
Room Temperature] in a dry place. LAMICTAL Tablets, 100-mg Peach, scored, shield-shaped tablets debossed with
"LAMICTAL" and "100", bottles of 100 (NDC 0173-0642-55). LAMICTAL Tablets, 150-mg Cream, scored, shield-shaped tablets debossed
with "LAMICTAL" and "150", bottles of 60 (NDC 0173-0643-60). LAMICTAL Tablets, 200-mg Blue, scored, shield-shaped tablets debossed
with "LAMICTAL" and "200", bottles of 60 (NDC 0173-0644-60). Store at 25��C (77��F);
excursions permitted to 15-30��C (59-86��F) [see USP Controlled
Room Temperature] in a dry place and protect from light. LAMICTAL Chewable
Dispersible Tablets, 2-mg White
to off-white, round tablets debossed with���LTG���over���2���, bottles of 30 (NDC 0173-0699-00). ORDER DIRECTLY
FROM GlaxoSmithKline 1-800-334-4153. LAMICTAL Chewable Dispersible Tablets, 5-mg White to off-white, caplet-shaped tablets
debossed with���GX CL2���, bottles of 100 (NDC 0173-0526-00). LAMICTAL Chewable Dispersible
Tablets, 25-mg White, super elliptical-shaped
tablets debossed with���GX CL5���, bottles of 100
(NDC 0173-0527-00). Store at 25��C (77��F); excursions permitted to 15-30��C
(59-86��F) [see USP Controlled Room Temperature] in a dry place. LAMICTAL Starter
Kit for Patients Taking Valproate 25-mg, white,
scored, shield-shaped tablets debossed with "LAMICTAL" and "25", blisterpack
of 35 tablets (NDC 0173-0633-10). Store at 25��C (77��F); excursions permitted
to 15-30��C (59-86��F) [see USP Controlled Room Temperature]
in a dry place. LAMICTAL Starter Kit for Patients Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone, or Rifampin
and Not Taking Valproate 25-mg, white, scored, shield-shaped
tablets debossed with "LAMICTAL" and "25" and 100-mg, peach, scored, shield-shaped tablets debossed with
"LAMICTAL" and���100���, blisterpack of 84, 25-mg tablets
and 14, 100-mg tablets (NDC 0173-0594-01) Store at 25��C (77��F); excursions permitted
to 15-30��C (59-86��F) [see USP Controlled Room Temperature]
in a dry place and protect from light. LAMICTAL Starter Kit for Patients Not Taking Carbamazepine, Phenytoin, Phenobarbital, Primidone,
Rifampin, or Valproate 25-mg, white, scored, shield-shaped tablets
debossed with "LAMICTAL" and "25" and 100-mg, peach, scored, shield-shaped tablets debossed with "LAMICTAL" and���100���, blisterpack of 42, 25-mg tablets and 7, 100-mg
tablets (NDC 0173-0594-02). Store at 25��C (77��F); excursions permitted
to 15-30��C (59-86��F) [see USP Controlled Room Temperature]
in a dry place and protect from light.
|
dailymed-instance:genericDr... | |
dailymed-instance:boxedWarn... |
SERIOUS RASHES REQUIRING
HOSPITALIZATION AND DISCONTINUATION OF TREATMENT HAVE BEEN REPORTED
IN ASSOCIATION WITH THE USE OF LAMICTAL. THE INCIDENCE OF THESE RASHES,
WHICH HAVE INCLUDED STEVENS-JOHNSON SYNDROME, IS APPROXIMATELY 0.8% (8 PER
1,000) IN PEDIATRIC PATIENTS (AGE<16 YEARS) RECEIVING LAMICTAL
AS ADJUNCTIVE THERAPY FOR EPILEPSY AND 0.3% (3 PER 1,000) IN
ADULTS ON ADJUNCTIVE THERAPY FOR EPILEPSY. IN CLINICAL TRIALS OF BIPOLAR
AND OTHER MOOD DISORDERS, THE RATE OF SERIOUS RASH WAS 0.08% (0.8
PER 1,000) IN ADULT PATIENTS RECEIVING LAMICTAL AS INITIAL MONOTHERAPY
AND 0.13% (1.3 PER 1,000) IN ADULT PATIENTS RECEIVING LAMICTAL AS
ADJUNCTIVE THERAPY. IN A PROSPECTIVELY FOLLOWED COHORT OF 1,983 PEDIATRIC
PATIENTS WITH EPILEPSY TAKING ADJUNCTIVE LAMICTAL, THERE WAS 1 RASH-RELATED
DEATH. IN WORLDWIDE POSTMARKETING EXPERIENCE, RARE CASES OF TOXIC
EPIDERMAL NECROLYSIS AND/OR RASH-RELATEDDEATH HAVE BEEN REPORTED
IN ADULT AND PEDIATRIC PATIENTS, BUT THEIR NUMBERS ARE TOO FEW TO
PERMIT A PRECISE ESTIMATE OF THE RATE. OTHER THAN AGE, THERE ARE AS YET NO
FACTORS IDENTIFIED THAT ARE KNOWN TO PREDICT THE RISK OF OCCURRENCE
OR THE SEVERITY OF RASH ASSOCIATED WITH LAMICTAL. THERE ARE SUGGESTIONS,
YET TO BE PROVEN, THAT THE RISK OF RASH MAY ALSO BE INCREASED BY (1)
COADMINISTRATION OF LAMICTAL WITH VALPROATE (INCLUDES VALPROIC ACID
AND DIVALPROEX SODIUM), (2) EXCEEDING THE RECOMMENDED INITIAL DOSE
OF LAMICTAL, OR (3) EXCEEDING THE RECOMMENDED DOSE ESCALATION FOR
LAMICTAL. HOWEVER, CASES HAVE BEEN REPORTED IN THE ABSENCE OF THESE
FACTORS. NEARLY ALL CASES OF LIFE-THREATENING RASHES ASSOCIATED WITH LAMICTAL
HAVE OCCURRED WITHIN 2 TO 8 WEEKS OF TREATMENT INITIATION. HOWEVER,
ISOLATED CASES HAVE BEEN REPORTED AFTER PROLONGED TREATMENT (E.G.,
6 MONTHS). ACCORDINGLY, DURATION OF THERAPY CANNOT BE RELIED
UPON AS A MEANS TO PREDICT THE POTENTIAL RISK HERALDED BY THEFIRST
APPEARANCE OF A RASH. ALTHOUGH BENIGN RASHES ALSO OCCUR WITH LAMICTAL,
IT IS NOT POSSIBLE TO PREDICT RELIABLY WHICH RASHES WILL PROVE TO
BE SERIOUS OR LIFE THREATENING. ACCORDINGLY, LAMICTAL SHOULD ORDINARILY
BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY
NOT DRUG RELATED. DISCONTINUATION OF TREATMENT MAY NOT PREVENT A RASH
FROM BECOMING LIFE THREATENING OR PERMANENTLY DISABLING OR DISFIGURING.
|
dailymed-instance:activeMoi... | |
dailymed-instance:inactiveI... | |
dailymed-instance:possibleD... |
diseasome-diseases:1056,
diseasome-diseases:1257,
diseasome-diseases:1688,
diseasome-diseases:176,
diseasome-diseases:2023,
diseasome-diseases:2307,
diseasome-diseases:2321,
diseasome-diseases:2335,
diseasome-diseases:2541,
diseasome-diseases:2542,
diseasome-diseases:2673,
diseasome-diseases:2742,
diseasome-diseases:278,
diseasome-diseases:2990,
diseasome-diseases:3250,
diseasome-diseases:3311,
diseasome-diseases:3531,
diseasome-diseases:372,
diseasome-diseases:377,
diseasome-diseases:3856,
diseasome-diseases:3857,
diseasome-diseases:3893,
diseasome-diseases:4131,
diseasome-diseases:488,
diseasome-diseases:546,
diseasome-diseases:582,
diseasome-diseases:691,
diseasome-diseases:787,
diseasome-diseases:804,
diseasome-diseases:898
|
dailymed-instance:precautio... |
Concomitant Use with Oral Contraceptives: Some estrogen-containing oral contraceptives have
been shown to decrease serum concentrations of lamotrigine (see PRECAUTIONS:
Drug Interactions). Dosage adjustments will
be necessary in most patients who start or stop estrogen-containing
oral contraceptives while taking LAMICTAL (see DOSAGE AND ADMINISTRATION:
Special Populations: Women and Oral Contraceptives: Adjustments to
the Maintenance Dose of LAMICTAL). During the week of inactive
hormone preparation (���pill-free���week) of oral contraceptive
therapy, plasma lamotrigine levels are expected to rise, as much as
doubling at the end of the week. Adverse events consistent with elevated
levels of lamotrigine, such as dizziness, ataxia, and diplopia, could
occur.<br/>Dermatological Events (see BOX WARNING, WARNINGS): Serious rashes associated with hospitalization and
discontinuation of LAMICTAL have been reported. Rare deaths have been
reported, but their numbers are too few to permit a precise estimate
of the rate. There are suggestions, yet to be proven, that the risk
of rash may also be increased by (1) coadministration of LAMICTAL
with valproate, (2) exceeding the recommended initial dose of LAMICTAL,
or (3) exceeding the recommended dose escalation for LAMICTAL. However,
cases have been reportedin the absence of these factors. In epilepsy clinical trials, approximately 10% of
all patients exposed to LAMICTAL developed a rash. In the Bipolar
Disorder clinical trials, 14% of patients exposed to LAMICTAL developed
a rash. Rashes associated with LAMICTAL do not appear to have unique
identifying features. Typically, rash occurs in the first 2 to 8 weeks
following treatment initiation. However, isolated cases have been
reported after prolonged treatment (e.g., 6 months). Accordingly,
duration of therapy cannot be relied upon as a means to predict the
potential risk heralded by the first appearance of a rash. Although most rashes resolved even with continuation
of treatment with LAMICTAL, it is not possible to predict reliably
which rashes will prove to be serious or life threatening. ACCORDINGLY, LAMICTAL SHOULD ORDINARILY BE DISCONTINUED
AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED.
DISCONTINUATION OF TREATMENT MAY NOT PREVENT A RASH FROM BECOMING
LIFE THREATENING OR PERMANENTLY DISABLING OR DISFIGURING. It is recommended that LAMICTAL not be
restarted in patients who discontinued due to rash associated with
prior treatment with LAMICTAL unless the potential benefits clearly
outweigh the risks. If the decision is made to restart a patient who
has discontinued LAMICTAL, the need to restart with the initial dosing
recommendations should be assessed. The greater the interval of time
since the previous dose, the greaterconsideration should be given
to restarting with the initial dosing recommendations. If a patient
has discontinued LAMICTAL for a period of more than 5 half-lives,
it is recommended that initial dosing recommendations and guidelines
be followed. The half-life of LAMICTAL is affected by other concomitant
medications (see CLINICAL PHARMACOLOGY: Pharmacokinetics and Drug
Metabolism, and DOSAGE AND ADMINISTRATION).<br/>Use in Patients With Epilepsy:<br/>Sudden Unexplained Death in Epilepsy (SUDEP): During the premarketing development of LAMICTAL,
20 sudden and unexplained deaths were recorded among a cohort of 4,700
patients with epilepsy (5,747 patient-years of exposure). Some of these could represent seizure-related deaths
in which the seizure was not observed, e.g., at night. This represents
an incidence of 0.0035 deaths per patient-year. Although this rate
exceeds that expected in a healthy population matched for age and
sex, it is within the range of estimates for the incidence of sudden
unexplained deaths in patients with epilepsy not receiving LAMICTAL
(ranging from 0.0005 for the general population of patients with epilepsy,
to 0.004 for a recently studied clinical trial population similar
to that in the clinical development program for LAMICTAL, to 0.005
for patients with refractory epilepsy). Consequently, whether these
figures are reassuring or suggest concern depends on the comparability
of the populations reported upon to the cohort receiving LAMICTAL
and the accuracy of the estimates provided. Probably most reassuring
is the similarity of estimated SUDEP rates in patients receiving LAMICTAL
and those receiving another antiepileptic drug that underwent clinical
testing in a similar population at about the same time. Importantly,
that drug is chemically unrelated to LAMICTAL. This evidence suggests,
although it certainly does not prove, that the high SUDEP rates reflect
population rates, not a drug effect.<br/>Status Epilepticus: Valid estimates of the incidence of treatment emergent
status epilepticus among patients treated with LAMICTAL are difficult
to obtain because reporters participating in clinical trials did not
all employ identical rules for identifying cases. At a minimum, 7
of 2,343 adult patients had episodes that could unequivocally be described
as status. In addition, a number of reports of variably defined episodes
of seizure exacerbation (e.g., seizure clusters, seizure flurries,
etc.) were made.<br/>Use in Patients With Bipolar Disorder:<br/>Acute Treatment of Mood Episodes: Safety and effectiveness of LAMICTAL in the acute
treatment of mood episodes has not been established.<br/>Children and Adolescents (less than 18 years of age): Treatment with antidepressants is associated with
an increased risk of suicidal thinking and behavior in children and
adolescents with major depressive disorder and other psychiatric disorders.
It is not known whether LAMICTAL is associated with a similar risk
in this population (see PRECAUTIONS: Clinical Worsening and Suicide
Risk Associated With Bipolar Disorder). Safety
and effectiveness of LAMICTAL in patients below the age of 18 years
with mood disorders have not been established.<br/>Clinical Worsening and Suicide Risk Associated With Bipolar
Disorder: Patients with bipolar disorder may experience worsening
of their depressive symptoms and/or the emergence of suicidal ideation
and behaviors (suicidality) whether or not they are taking medications
for bipolar disorder. Patients should be closely monitored for clinical
worsening (including development of new symptoms) and suicidality,
especially at the beginning of a course of treatment, or at the time
of dose changes. In addition, patients with
a history of suicidal behavior or thoughts, those patients exhibiting
a significant degree of suicidal ideation prior to commencement of
treatment, and young adults, are at an increased risk of suicidal
thoughts or suicide attempts, and should receive careful monitoring
during treatment. Patients (and caregivers
of patients) should be alerted about the need to monitor for any worsening
of their condition (including development of new symptoms) and /or
the emergence of suicidal ideation/behavior or thoughts of harming
themselves and to seek medical advice immediately if these symptoms
present. Consideration should be given to
changing the therapeutic regimen, including possibly discontinuing
the medication, in patients who experience clinical worsening (including
development of new symptoms) and/or the emergence of suicidal ideation/behavior
especially if these symptoms are severe, abrupt in onset, or were
not part of the patient's presenting symptoms. Prescriptions for LAMICTAL should be written for the smallest
quantity of tablets consistent with good patient management, in order
to reduce the risk of overdose. Overdoses have been reported for LAMICTAL,
some of which have been fatal (see OVERDOSAGE).<br/>Addition of LAMICTAL to a Multidrug Regimen That Includes Valproate
(Dosage Reduction): Because valproate reduces the clearance of lamotrigine,
the dosage of lamotrigine in the presence of valproate is less than
half of that required in its absence (see DOSAGE AND ADMINISTRATION).<br/>Use in Patients With Concomitant Illness: Clinical experience with LAMICTAL in patients with
concomitant illness is limited. Caution is advised when using LAMICTAL
in patients with diseases or conditions that could affect metabolism
or elimination of the drug, such as renal, hepatic, or cardiac functional
impairment. Hepatic metabolism to the glucuronide
followed by renal excretion is the principal route of elimination
of lamotrigine (see CLINICAL PHARMACOLOGY). A study in individuals with severe chronic renal failure (mean
creatinine clearance = 13 mL/min) not receiving other
AEDs indicated that the elimination half-life of unchanged lamotrigine
is prolonged relative to individuals with normal renal function. Until
adequate numbers of patients with severe renal impairment have been
evaluated during chronic treatment with LAMICTAL, it should be used
with caution in these patients, generally using a reduced maintenance
dose for patients with significant impairment. Because there is limited experience with the use of LAMICTAL
in patients with impaired liver function, the use in such patients
may be associated with as yet unrecognized risks (see CLINICAL PHARMACOLOGY
and DOSAGE AND ADMINISTRATION).<br/>Binding in the Eye and Other Melanin-Containing Tissues: Because lamotrigine binds to melanin, it could accumulate
in melanin-rich tissues over time. This raises the possibility that
lamotrigine may cause toxicity in these tissues after extended use.
Although ophthalmological testing was performed in one controlled
clinical trial, the testing was inadequate to exclude subtle effects
or injury occurring after long-term exposure. Moreover, the capacity
of available tests to detect potentially adverse consequences, if
any, of lamotrigine's binding to melanin is unknown. Accordingly, although there are no specific recommendations for
periodic ophthalmological monitoring, prescribers should be aware
of the possibility of long-term ophthalmologic effects.<br/>Information for Patients: Prior to initiation of treatment with LAMICTAL,
the patient should be instructed that a rash or other signs or symptoms
of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious
medical event and that the patient should report any such occurrence
to a physician immediately. In addition, the patient should notify
his or her physician if worsening of seizure control occurs. Patients should be advised that LAMICTAL may cause
dizziness, somnolence, and other symptoms and signs of central nervous
system (CNS) depression. Accordingly, they should be advised neither
to drive a car nor to operate other complex machinery until they have
gained sufficient experience on LAMICTAL to gauge whether or not it
adversely affects their mental and/or motor performance. Patients should be advised to notify their physicians
if they become pregnant or intend to become pregnant during therapy.
Patients should be advised to notify their physicians if they intend
to breastfeed or are breastfeeding an infant. Women should be advised to notify their physician if they plan
to start or stop use of oral contraceptives or other female hormonal
preparations. Starting estrogen-containing oral contraceptives may
significantly decrease lamotrigine plasma levels and stopping estrogen-containing
oral contraceptives (including the���pill free���week)
may significantly increase lamotrigine plasma levels (see PRECAUTIONS:
Drug Interactions). Women should also be advised to promptly notify
their physician if they experience adverse events or changes in menstrual
pattern (e.g., break-through bleeding) while receiving LAMICTAL in
combination with these medications. Patients
should be advised to notify their physician if they stop taking LAMICTAL
for any reason and not to resume LAMICTAL without consulting their
physician. Patients should be informed of
the availability of a patient information leaflet, and they should
be instructed to read the leaflet prior to taking LAMICTAL. See PATIENT
INFORMATION at the end of this labeling for the text of the leaflet
provided for patients.<br/>Laboratory Tests: The value of monitoring plasma concentrations of
LAMICTAL has not been established. Because of the possible pharmacokinetic
interactions between LAMICTAL and other drugs including AEDs (see
Table 3), monitoring of the plasma levels of LAMICTAL and concomitant
drugs may be indicated, particularly during dosage adjustments. In
general, clinical judgment should be exercised regarding monitoring
of plasma levels of LAMICTAL and other drugs and whether or not dosage
adjustments are necessary.<br/>Drug Interactions: The net effects of drug interactions with LAMICTAL
are summarized in Table 3 (see also DOSAGE AND ADMINISTRATION).<br/>Oral Contraceptives: In 16 female volunteers, an oral contraceptive
preparation containing 30 mcg ethinylestradiol and 150 mcg
levonorgestrel increased the apparent clearance of lamotrigine (300 mg/day)
by approximately 2-fold with a mean decrease in AUC of 52% and in
Cof 39%. In this study, trough serum lamotrigine concentrations
gradually increased and were approximately 2-fold higher on average
at the end of the week of the inactive hormone preparation compared
to trough lamotrigine concentrations at the end of the active hormone
cycle. Gradual transient increases in lamotrigine
levels (approximate 2-fold increase) occurred during the week of inactive
hormone preparation (���pill-free���week) for women not
also taking a drug that increased the clearance of lamotrigine (carbamazepine,
phenytoin, phenobarbital, primidone, or rifampin). The increase in
lamotrigine plasma levels will be greater if the dose of LAMICTAL
is increased in the few days before or during the���pill-free���week. Increases in lamotrigine plasma levels could result in dose-dependent
adverse effects (see PRECAUTIONS: Concomitant Use With Oral Contraceptives). In the same study, coadministration of LAMICTAL (300 mg/day)
in 16 female volunteers did not affect the pharmacokinetics of
the ethinylestradiol component of the oral contraceptive preparation.
There was a mean decrease in the AUC and Cof the levonorgestrel
component of 19% and 12%, respectively. Measurement of serum progesterone
indicated that there was no hormonal evidence of ovulation in any
of the 16 volunteers, although measurement of serum FSH, LH,
and estradiol indicated that there was some loss of suppression of
the hypothalamic-pituitary-ovarian axis. The
effects of doses of LAMICTAL other than 300 mg/day have not been
systematically evaluated in controlled clinical trials. The clinical significance of the observed hormonal
changes on ovulatory activity is unknown. However, the possibility
of decreased contraceptive efficacy in some patients cannot be excluded.
Therefore, patients should be instructed to promptly report changes
in their menstrual pattern (e.g., break-through bleeding). Dosage adjustments will be necessary for most women
receiving estrogen-containing oral contraceptive preparations (see
DOSAGE AND ADMINISTRATION: Special Populations: Women and Oral Contraceptives).<br/>Other Hormonal Contraceptives or Hormone Replacement Therapy: The effect of other hormonal contraceptive preparations
or hormone replacement therapy on the pharmacokinetics of lamotrigine
has not been systematically evaluated. It has been reported that ethinylestradiol,
not progestogens, increased the clearance of lamotrigine up to 2���fold,
and the progestin only pills had no effect on lamotrigine plasma levels.
Therefore, adjusments to the dosage of LAMICTAL in the presence of
progestogens alone will likely not be needed.<br/>Bupropion: The pharmacokinetics of a 100-mg single dose of
LAMICTAL in healthy volunteers (n = 12) were not changed
by coadministration of bupropion sustained-release formulation (150 mg
twice a day) starting 11 days before LAMICTAL.<br/>Carbamazepine: LAMICTAL has no appreciable effect on steady-state
carbamazepine plasma concentration. Limited clinical data suggest
there is a higher incidence of dizziness, diplopia, ataxia, and blurred
vision in patients receiving carbamazepine with LAMICTAL than in patients
receiving other AEDs with LAMICTAL (see ADVERSE REACTIONS). The mechanism
of this interaction is unclear. The effect of LAMICTAL on plasma concentrations
of carbamazepine-epoxide is unclear. In a small subset of patients
(n = 7) studied in a placebo-controlled trial, LAMICTAL
had no effect on carbamazepine-epoxide plasma concentrations, but
in a small, uncontrolled study (n = 9), carbamazepine-epoxide
levels increased. The addition of carbamazepine
decreases lamotrigine steady-state concentrations by approximately
40%.<br/>Felbamate: In a study of 21 healthy volunteers, coadministration
of felbamate (1,200 mg twice daily) with LAMICTAL (100 mg twice daily
for 10 days) appeared to have no clinically relevant effects on the
pharmacokinetics of lamotrigine.<br/>Folate Inhibitors: Lamotrigine is a weak inhibitor of dihydrofolate
reductase. Prescribers should be aware of this action when prescribing
other medications that inhibit folate metabolism.<br/>Gabapentin: Based on a retrospective analysis of plasma levels
in 34 patients who received LAMICTAL both with and without gabapentin,
gabapentin does not appear to change the apparent clearance of lamotrigine.<br/>Levetiracetam: Potential
drug interactions between levetiracetam and LAMICTAL were assessed
by evaluating serum concentrations of both agents during placebo-controlled
clinical trials. These data indicate that LAMICTAL does not influence
the pharmacokinetics of levetiracetam and that levetiracetam does
not influence the pharmacokinetics of LAMICTAL.<br/>Lithium: The pharmacokinetics of lithium were not altered
in healthy subjects (n = 20) by coadministration of LAMICTAL
(100 mg/day) for 6 days.<br/>Olanzapine: The AUC and Cof olanzapine were similar
following the addition of olanzapine (15 mg once daily) to LAMICTAL
(200 mg once daily) in healthy male volunteers (n = 16)
compared to the AUC and Cin healthy male volunteers
receiving olanzapine alone (n = 16). In the same study, the AUC and Cof lamotrigine
was reduced on average by 24% and 20%, respectively, following the
addition of olanzapine to LAMICTAL in healthy male volunteers compared
to those receiving LAMICTAL alone. This reduction in lamotrigine plasma
concentrations is not expected to be clinically relevant.<br/>Oxcarbazepine: The AUC and Cof oxcarbazepine and
its active 10-monohydroxy oxcarbazepine metabolite were not significantly
different following the addition of oxcarbazepine (600 mg twice
daily) to LAMICTAL (200 mg once daily) in healthy male volunteers
(n = 13) compared to healthy male volunteers receiving oxcarbazepine
alone (n = 13). In the same study,
the AUC and Cof lamotrigine were similar following
the addition of oxcarbazepine (600 mg twice daily) to LAMICTAL
in healthy male volunteers compared to those receiving LAMICTAL alone.
Limited clinical data suggest a higher incidence of headache, dizziness,
nausea, and somnolence with coadministration of LAMICTAL and oxcarbazepine
compared to LAMICTAL alone or oxcarbazepine alone.<br/>Phenobarbital, Primidone: The addition of phenobarbital or primidone decreases
lamotrigine steady-state concentrations by approximately 40%.<br/>Phenytoin: LAMICTAL has no appreciable effect on steady-state
phenytoin plasma concentrations in patients with epilepsy. The addition
of phenytoin decreases lamotrigine steady-state concentrations by
approximately 40%.<br/>Pregabalin: Steady-state trough plasma concentrations of lamotrigine
were not affected by concomitant pregabalin (200 mg 3 times daily)
administration. There are no pharmacokinetic interactions between
LAMICTAL and pregabalin<br/>Rifampin: In 10 male volunteers, rifampin (600 mg/day
for 5 days) significantly increased the apparent clearance of
a single 25 mg dose of LAMICTAL by approximately 2-fold (AUC
decreased by approximately 40%).<br/>Topiramate: Topiramate resulted in no change in plasma concentrations
of lamotrigine. Administration of LAMICTAL resulted in a 15% increase
in topiramate concentrations.<br/>Valproate: When LAMICTAL was administered to healthy volunteers
(n = 18) receiving valproate, the trough steady-state valproate
plasma concentrations decreased by an average of 25% over a 3-week
period, and then stabilized. However, adding LAMICTAL to the existing
therapy did not cause a change in valproate plasma concentrations
in either adult or pediatric patients in controlled clinical trials. The addition of valproate increased lamotrigine steady-state
concentrations in normal volunteers by slightly more than 2-fold.
In one study, maximal inhibition of lamotrigine clearance was reached
at valproate doses between 250 mg/day and 500 mg/day and
did not increase as the valproate dose was further increased.<br/>Zonisamide: In a study of 18 patients with epilepsy, co-administration
of zonisamide (200 to 400 mg/day) with LAMICTAL (150 to 500 mg/day)
for 35 days had no significant effect on the pharmacokinetics of lamotrigine.<br/>Known Inducers or Inhibitors of Glucuronidation: Drugs other than
those listed above have not been systematically evaluated in combination
with LAMICTAL. Since lamotrigine is metabolized predominately by glucuronic
acid conjugation, drugs that are known to induce or inhibit glucuronidation
may affect the apparent clearance of lamotrigine and doses of LAMICTAL
may require adjustment based on clinical response.<br/>Other: Results of in vitro experiments suggest that clearance
of lamotrigine is unlikely to be reduced by concomitant administration
of amitriptyline, clonazepam, clozapine, fluoxetine, haloperidol,
lorazepam, phenelzine, risperidone, sertraline, or trazodone (see
CLINICAL PHARMACOLOGY: Pharmacokinetics and Drug Metabolism). Results of in vitro experiments suggest that lamotrigine
does not reduce the clearance of drugs eliminated predominantly by
CYP2D6 (see CLINICAL PHARMACOLOGY). From adjunctive
clinical trials and volunteer studies. Net effects were estimated
by comparing the mean clearance values obtained in adjunctive clinical
trials and volunteers studies. The effect of other hormonal contraceptive preparations
or hormone replacement therapy on the pharmacokinetics of lamotrigine
has not been systematically evaluated in clinical trials, and the
effect may not be similar to that seen with the ethinylestradiol/levonorgestrel
combinations. Modest decrease in levonorgestrel (see PRECAUTIONS: Drug Interactions:
Oral Contraceptives). Not administered, but an active metabolite of carbamazepine. Slight decrease,
not expected to be clinically relevant. Not administered, but an active metabolite
of oxcarbazepine. Slight increase
not expected to be clinically relevant. ���= No significant effect. ? = Conflicting data.<br/>Drug/Laboratory Test Interactions: None known.<br/>Carcinogenesis, Mutagenesis, Impairment of Fertility: No evidence of carcinogenicity was seen in 1 mouse
study or 2 rat studies following oral administration of lamotrigine
for up to 2 years at maximum tolerated doses (30 mg/kg per
day for mice and 10 to 15 mg/kg per day for rats, doses that
are equivalent to 90 mg/mand 60 to 90 mg/m, respectively). Steady-state plasma concentrations ranged
from 1 to 4 mcg/mL in the mouse study and 1 to 10 mcg/mL
in the rat study. Plasma concentrations associated with the recommended
human doses of 300 to 500 mg/day are generally in the range of
2 to 5 mcg/mL, but concentrations as high as 19 mcg/mL have
been recorded. Lamotrigine was not mutagenic
in the presence or absence of metabolic activation when tested in
2 gene mutation assays (the Ames test and the in vitro mammalian mouse
lymphoma assay). In 2 cytogenetic assays (the in vitro human lymphocyte
assay and the in vivo rat bone marrow assay), lamotrigine did not
increase the incidence of structural or numerical chromosomal abnormalities. No evidence of impairment of fertility was detected
in rats given oral doses of lamotrigine up to 2.4 times the highest
usual human maintenance dose of 8.33 mg/kg per day or 0.4 times
the human dose on a mg/mbasis. The effect of lamotrigine
on human fertility is unknown.<br/>Pregnancy:<br/>Teratogenic Effects: Pregnancy Category C. No evidence of teratogenicity
was found in mice, rats, or rabbits when lamotrigine was orally administered
to pregnant animals during the period of organogenesis at doses up
to 1.2, 0.5, and 1.1 times, respectively, on a mg/mbasis,
the highest usual human maintenance dose (i.e., 500 mg/day).
However, maternal toxicity and secondary fetal toxicity producing
reduced fetal weight and/or delayed ossification were seen in mice
and rats, but not in rabbits at these doses. Teratology studies were
also conducted using bolus intravenous administration of the isethionate
salt of lamotrigine in rats and rabbits. In rat dams administered
an intravenous dose at 0.6 times the highest usual human maintenance
dose, the incidence of intrauterine death without signs of teratogenicity
was increased. A behavioral teratology study
was conducted in rats dosed during the period of organogenesis. At
day 21 postpartum, offspring of dams receiving 5 mg/kg per day
or higher displayed a significantly longer latent period for open
field exploration and a lower frequency of rearing. In a swimming
maze test performed on days 39 to 44 postpartum, time to completion
was increased in offspring of dams receiving 25 mg/kg per day.
These doses represent 0.1 and 0.5 times the clinical dose on a mg/mbasis, respectively. Lamotrigine
did not affect fertility, teratogenesis, or postnatal development
when rats were dosed prior to and during mating, and throughout gestation
and lactation at doses equivalent to 0.4 times the highest usual human
maintenance dose on a mg/mbasis. When pregnant rats were orally dosed at 0.1, 0.14, or 0.3 times
the highest human maintenance dose (on a mg/mbasis) during
the latter part of gestation (days 15 to 20), maternal toxicity and
fetal death were seen. In dams, food consumption and weight gain were
reduced, and the gestation period was slightly prolonged (22.6 vs.
22.0 days in the control group). Stillborn pups were found in all
3 drug-treated groups with the highest number in the high-dose group.
Postnatal death was also seen, but only in the 2 highest doses, and
occurred between day 1 and 20. Some of these deaths appear to be drug-related
and not secondary to the maternal toxicity. A no-observed-effect level
(NOEL) could not be determined for this study. Although LAMICTAL was not found to be teratogenic in the above
studies, lamotrigine decreases fetal folate concentrations in rats,
an effect known to be associated with teratogenesis in animals and
humans. There are no adequate and well-controlled studies in pregnant
women. Because animal reproduction studies are not always predictive
of human response, this drug should be used during pregnancy only
if the potential benefit justifies the potential risk to the fetus.<br/>Non-Teratogenic Effects: As with other antiepileptic drugs, physiological
changes during pregnancy may affect lamotrigine concentrations and/or
therapeutic effect. There have been reports of decreased lamotrigine
concentrations during pregnancy and restoration of pre-partum concentrations
after delivery. Dosage adjustments may be necessary to maintain clinical
response.<br/>Pregnancy Exposure Registry: To facilitate monitoring fetal outcomes of pregnant
women exposed to lamotrigine, physicians are encouraged to register
patients, before fetal outcome (e.g., ultrasound,
results of amniocentesis, birth, etc.) is known, and can
obtain information by calling the Lamotrigine Pregnancy Registry at
(800) 336-2176 (toll-free). Patients can enroll themselves in
the North American Antiepileptic Drug Pregnancy Registry by calling
(888) 233-2334 (toll-free).<br/>Labor and Delivery: The effect of LAMICTAL on labor and delivery in
humans is unknown.<br/>Use in Nursing Mothers: Preliminary data indicate that lamotrigine passes
into human milk. Because the effects on the infant exposed to LAMICTAL
by this route are unknown, breastfeeding while taking LAMICTAL is
not recommended.<br/>Pediatric Use: LAMICTAL is indicated as adjunctive therapy for
partial seizures, the generalized seizures of Lennox-Gastaut syndrome,
and primary generalized tonic-clonic seizures in patients above 2 years
of age. Safety and effectiveness in patients
below the age of 18 years with Bipolar Disorder has not been established.<br/>Geriatric Use: Clinical studies of LAMICTAL for epilepsy and in
Bipolar Disorder did not include sufficient numbers of subjects aged
65 and over to determine whether they respond differently from younger
subjects. In general, dose selection for an elderly patient should
be cautious, usually starting at the low end of the dosing range,
reflecting the greater frequency of decreased hepatic, renal, or cardiac
function, and of concomitant disease or other drug therapy.
|
dailymed-instance:overdosag... |
Human Overdose Experience: Overdoses involving quantities up to 15 g have
been reported for LAMICTAL, some of which have been fatal. Overdose
has resulted in ataxia, nystagmus, increased seizures, decreased level
of consciousness, coma, and intraventricular conduction delay.<br/>Management of Overdose: There are no specific antidotes for LAMICTAL. Following
a suspected overdose, hospitalization of the patient is advised. General
supportive care is indicated, including frequent monitoring of vital
signs and close observation of the patient. If indicated, emesis should
be induced or gastric lavage should be performed; usual precautions
should be takento protect the airway. It should be kept in mind that
lamotrigine is rapidly absorbed (see CLINICAL PHARMACOLOGY). It is
uncertain whether hemodialysis is an effective means of removing lamotrigine
from the blood. In 6 renal failure patients, about 20% of the amount
of lamotrigine in the body was removed by hemodialysis during a 4-hour
session. A Poison Control Center should be contacted for information
on the management of overdosage of LAMICTAL.
|
dailymed-instance:genericMe... |
lamotrigine
|
dailymed-instance:fullName |
LAMICTAL (Tablet)
|
dailymed-instance:adverseRe... |
SERIOUS RASH REQUIRING
HOSPITALIZATION AND DISCONTINUATION OF LAMICTAL, INCLUDING STEVENS-JOHNSON
SYNDROME AND TOXIC EPIDERMAL NECROLYSIS, HAVE OCCURRED IN ASSOCIATION
WITH THERAPY WITH LAMICTAL. RARE DEATHS HAVE BEEN REPORTED, BUT THEIR
NUMBERS ARE TOO FEW TO PERMIT A PRECISE ESTIMATE OF THE RATE (see
BOX WARNING).<br/>Epilepsy:<br/>Most Common Adverse Events in All Clinical Studies:<br/>Incidence in Controlled Clinical Studies of Epilepsy: The prescriber
should be aware that the figures in Tables 4, 5, 6, and 7 cannot be
used to predict the frequency of adverse experiences in the course
of usual medical practice where patient characteristics and other
factors may differ from those prevailing during clinical studies.
Similarly, the cited frequencies cannot be directly compared with
figures obtained from other clinical investigations involving different
treatments, uses, or investigators. An inspection of these frequencies,
however, does provide the prescriber with one basis to estimate the
relative contribution of drug and nondrug factors to the adverse event
incidences in the population studied.<br/>Body as a Whole: Asthenia, fever.<br/>Digestive: Anorexia,
dry mouth, rectal hemorrhage, peptic ulcer.<br/>Metabolic and Nutritional: Peripheral edema.<br/>Nervous System: Amnesia, ataxia, depression, hypesthesia, libido
increase, decreased reflexes, increased reflexes, nystagmus, irritability,
suicidal ideation.<br/>Respiratory: Epistaxis, bronchitis, dyspnea.<br/>Skin and Appendages: Contact dermatitis, dry skin, sweating.<br/>Special Senses: Vision abnormality.<br/>Incidence in Controlled Clinical Studies of LAMICTAL for the
Maintenance Treatment of Bipolar I Disorder: Table 8 lists treatment-emergent signs and symptoms
that occurred in at least 5% of patients with Bipolar Disorder treated
with LAMICTAL monotherapy (100 to 400 mg/day), following the
discontinuation of other psychotropic drugs, in 2 double-blind,
placebo-controlled trials of 18 months' duration and were
numerically more frequent than in the placebo group. * Patients in these studies
were converted to LAMICTAL (100 to 400 mg/day) or placebo monotherapy
from add-on therapy with other psychotropic medications. Patients
may have reported multiple adverse experiences during the study; thus,
patients may be included in more than one category. ���Adverse experiences reported by at least
5% of patients are included. ���In the overall bipolar and other mood disorders clinical
trials, the rate of serious rash was 0.08% (1 of 1,233) of adult patients
who received LAMICTAL as initial monotherapy and 0.13% (2 of 1,538)
of adult patients who received LAMICTAL as adjunctive therapy (see
WARNINGS). These adverse events were usually
mild to moderate in intensity. Other events
that occurred in 5% or more patients but equally or more frequently
in the placebo group included: dizziness, mania, headache, infection,
influenza, pain, accidental injury, diarrhea, and dyspepsia. Adverse events that occurred with a frequency of less
than 5% and greater than 1% of patients receiving LAMICTAL and numerically
more frequent than placebo were:<br/>General: Fever, neck pain.<br/>Cardiovascular: Migraine.<br/>Digestive: Flatulence.<br/>Metabolic and Nutritional: Weight gain, edema.<br/>Musculoskeletal: Arthralgia, myalgia.<br/>Nervous System: Amnesia, depression, agitation, emotional lability,
dyspraxia, abnormal thoughts, dream abnormality, hypoesthesia.<br/>Respiratory: Sinusitis.<br/>Urogenital: Urinary frequency.<br/>Adverse Events Following Abrupt Discontinuation: In the 2 maintenance trials, there was no increase
in the incidence, severity or type of adverse events in Bipolar Disorder
patients after abruptly terminating LAMICTAL therapy. In clinical
trials in patients with Bipolar Disorder, 2 patients experienced
seizures shortly after abrupt withdrawal of LAMICTAL. However, there
were confounding factors that may have contributed to the occurrence
of seizures in these bipolar patients (see DOSAGE AND ADMINISTRATION).<br/>Mania/Hypomania/Mixed Episodes: During the double-blind,
placebo-controlled clinical trials in Bipolar I Disorder in which
patients were converted to LAMICTAL monotherapy (100 to 400 mg/day)
from other psychotropic medications and followed for durations up
to 18 months, the rate of manic or hypomanic or mixed mood episodes
reported as adverse experiences was 5% for patients treated with LAMICTAL
(n = 227), 4% for patients treated with lithium (n = 166),
and 7% for patients treated with placebo (n = 190). In all
bipolar controlled trials combined, adverse events of mania (including
hypomania and mixed mood episodes) were reported in 5% of patients
treated with LAMICTAL (n = 956), 3% of patients treated
with lithium (n = 280), and 4% of patients treated with
placebo (n = 803). The overall
adverse event profile for LAMICTAL was similar between females and
males, between elderly and nonelderly patients, and among racial groups.<br/>Other Adverse Events Observed During All Clinical Trials For
Pediatric and Adult Patients With Epilepsy or Bipolar Disorder and
Other Mood Disorders: LAMICTAL has been administered to 6,694 individuals
for whom complete adverse event data was captured during all clinical
trials, only some of which were placebo controlled. During these trials,
all adverse events were recorded by the clinical investigators using
terminology of their own choosing. To provide a meaningful estimate
of the proportion of individuals having adverse events, similar types
of events were grouped into a smaller number of standardized categories
using modified COSTART dictionary terminology. The frequencies presentedrepresent the proportion of the 6,694 individuals exposed to LAMICTAL
who experienced an event of the type cited on at least one occasion
while receiving LAMICTAL. All reported events are included except
those already listed in the previous tables or elsewhere in the labeling,
those too general to be informative, and those not reasonably associated
with the use of the drug. Events are further
classified within body system categories and enumerated in order of
decreasing frequency using the following definitions: frequent adverse events are defined
as those occurring in at least 1/100 patients; infrequent adverse events are those
occurring in 1/100 to 1/1,000 patients; rare adverse events are those occurring in fewer than 1/1,000
patients.<br/>Body as a Whole: Infrequent: Allergic reaction, chills, halitosis, and malaise. Rare: Abdomen enlarged, abscess,
and suicide/suicide attempt.<br/>Cardiovascular System: Infrequent: Flushing, hot flashes, hypertension, palpitations, postural hypotension,
syncope, tachycardia, and vasodilation. Rare: Angina pectoris, atrial fibrillation, deep thrombophlebitis,
ECG abnormality, and myocardial infarction.<br/>Dermatological: Infrequent: Acne, alopecia, hirsutism, maculopapular rash, skin discoloration,
and urticaria. Rare: Angioedema,
erythema, exfoliative dermatitis, fungal dermatitis, herpes zoster,
leukoderma, multiforme erythema, petechial rash, pustular rash, seborrhea,
Stevens-Johnson syndrome, and vesiculobullous rash.<br/>Digestive System: Infrequent: Dysphagia, eructation, gastritis, gingivitis, increased appetite,
increased salivation, liver function tests abnormal, and mouth ulceration. Rare: Gastrointestinal hemorrhage,
glossitis, gum hemorrhage, gum hyperplasia, hematemesis, hemorrhagic
colitis, hepatitis, melena, stomach ulcer, stomatitis, thirst, and
tongue edema.<br/>Endocrine System: Rare: Goiter and hypothyroidism.<br/>Hematologic and Lymphatic System: Infrequent: Ecchymosis and leukopenia.Rare: Anemia, eosinophilia,
fibrin decrease, fibrinogen decrease, iron deficiency anemia, leukocytosis,
lymphocytosis, macrocytic anemia, petechia, and thrombocytopenia.<br/>Metabolic and Nutritional Disorders: Infrequent: Aspartate transaminase increased. Rare: Alcohol intolerance, alkaline phosphatase increase,
alanine transaminase increase, bilirubinemia, general edema, gamma
glutamyl transpeptidase increase, and hyperglycemia.<br/>Musculoskeletal System: Infrequent: Arthritis, leg cramps, myasthenia, and twitching. Rare: Bursitis, joint disorder,
muscle atrophy, pathological fracture, and tendinous contracture.<br/>Nervous System: Frequent: Confusion and paresthesia.Infrequent: Akathisia, apathy, aphasia, CNS depression, depersonalization, dysarthria,
dyskinesia, euphoria, hallucinations, hostility, hyperkinesia, hypertonia,
libido decreased, memory decrease, mind racing, movement disorder,
myoclonus, panic attack, paranoid reaction, personality disorder,
psychosis, sleep disorder, stupor, and suicidal ideation. Rare: Cerebellar syndrome, cerebrovascular
accident, cerebral sinus thrombosis, choreoathetosis, CNS stimulation,
delirium, delusions, dysphoria, dystonia, extrapyramidal syndrome,
faintness, grand mal convulsions, hemiplegia, hyperalgesia, hyperesthesia,
hypokinesia, hypotonia, manic depression reaction, muscle spasm, neuralgia,
neurosis, paralysis, and peripheralneuritis.<br/>Respiratory System: Infrequent: Yawn. Rare: Hiccup and
hyperventilation.<br/>Special Senses: Frequent: Amblyopia. Infrequent: Abnormality of accommodation, conjunctivitis, dry eyes,
ear pain, photophobia, taste perversion, and tinnitus. Rare: Deafness, lacrimation disorder,
oscillopsia, parosmia, ptosis, strabismus, taste loss, uveitis, and
visual field defect.<br/>Urogenital System: Infrequent: Abnormal ejaculation, breast pain, hematuria, impotence, menorrhagia,
polyuria, urinary incontinence, and urine abnormality.Rare: Acute kidney failure, anorgasmia, breast abscess, breast neoplasm,
creatinine increase, cystitis, dysuria, epididymitis, female lactation,
kidney failure, kidney pain, nocturia, urinary retention, urinary
urgency, and vaginal moniliasis.<br/>Postmarketing and Other Experience: In addition to the adverse experiences reported
during clinical testing of LAMICTAL, the following adverse experiences
have been reported in patients receiving marketed LAMICTAL and from
worldwide noncontrolled investigational use. These adverse experiences
have not been listed above, and data are insufficient to support an
estimate of their incidence or to establish causation.<br/>Blood and Lymphatic: Agranulocytosis, aplastic anemia, disseminated intravascular
coagulation, hemolytic anemia, neutropenia, pancytopenia, red cell
aplasia.<br/>Gastrointestinal: Esophagitis.<br/>Hepatobiliary Tract and Pancreas: Pancreatitis.<br/>Immunologic: Lupus-like
reaction, vasculitis.<br/>Lower Respiratory: Apnea.<br/>Musculoskeletal: Rhabdomyolysis has been observed in patients experiencing
hypersensitivity reactions.<br/>Neurology: Exacerbation of parkinsonian symptoms in patients
with pre-existing Parkinson's disease, tics.<br/>Non-site Specific: Hypersensitivity reaction, multiorgan failure, progressive
immunosuppression.
|
dailymed-instance:warning |
SEE BOX WARNING REGARDING
THE RISK OF SERIOUS RASHES REQUIRING HOSPITALIZATION AND DISCONTINUATION
OF LAMICTAL. ALTHOUGH BENIGN RASHES ALSO OCCUR WITH LAMICTAL, IT IS NOT POSSIBLE
TO PREDICT RELIABLY WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE
THREATENING. ACCORDINGLY, LAMICTAL SHOULD ORDINARILY BE DISCONTINUED
AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED.
DISCONTINUATION OF TREATMENT MAY NOT PREVENT A RASH FROM BECOMING
LIFE THREATENING OR PERMANENTLY DISABLING OR DISFIGURING.<br/>Serious Rash:<br/>Pediatric Population: The incidence of serious rash associated with hospitalization
and discontinuation of LAMICTAL in a prospectively followed cohort
of pediatric patients with epilepsy receiving adjunctive therapy was
approximately 0.8% (16 of 1,983). When 14 of these cases were reviewed
by 3 expert dermatologists, there was considerable disagreement as
to their proper classification. To illustrate, one dermatologist considered
none of the cases to be Stevens-Johnson syndrome; another assigned
7 of the 14 to this diagnosis. There was 1 rash-related death in this
1,983 patient cohort. Additionally, there have been rare cases of
toxic epidermal necrolysis with and without permanent sequelae and/or
death in US and foreign postmarketing experience. There is evidence that the inclusion of valproate in a multidrug
regimen increases the risk of serious, potentially life-threatening
rash in pediatric patients. In pediatric patients who used valproate
concomitantly, 1.2% (6 of 482) experienced a serious rash compared
to 0.6% (6 of 952) patients not taking valproate.<br/>Adult Population: Serious rash associated with hospitalization and
discontinuation of LAMICTAL occurred in 0.3% (11 of 3,348) of adult
patients who received LAMICTAL in premarketing clinical trials of
epilepsy. In the bipolar and other mood disorders clinical trials,
the rate of serious rash was 0.08% (1 of 1,233) of adult patients
who received LAMICTAL as initial monotherapy and 0.13% (2 of 1,538)
of adult patients who received LAMICTAL as adjunctive therapy. No
fatalities occurred among these individuals. However, in worldwide
postmarketing experience, rare cases of rash-related death have been
reported, but their numbers are too few to permit a precise estimate
of the rate. Among the rashes leading to
hospitalization were Stevens-Johnson syndrome, toxic epidermal necrolysis,
angioedema, and a rash associated with a variable number of the following
systemic manifestations: fever, lymphadenopathy, facial swelling,
hematologic, and hepatologic abnormalities. There is evidence that the inclusion of valproate in a multidrug
regimen increases the risk of serious, potentially life-threatening
rash in adults. Specifically, of 584 patients administered LAMICTAL
with valproate in epilepsy clinical trials, 6 (1%) were hospitalized
in association with rash; in contrast, 4 (0.16%) of 2,398 clinical
trial patients and volunteers administered LAMICTAL in the absence
of valproate were hospitalized. Other examples
of serious and potentially life-threatening rash that did not lead
to hospitalization also occurred in premarketing development. Among
these, 1 case was reported to be Stevens-Johnson���like.<br/>Hypersensitivity Reactions: Hypersensitivity reactions, some fatal or life threatening,
have also occurred. Some of these reactions have included clinical
features of multiorgan failure/dysfunction, including hepatic abnormalities
and evidence of disseminated intravascular coagulation. It is important
to note that early manifestations of hypersensitivity (e.g., fever,
lymphadenopathy) may be present even though a rash is not evident.
If such signs or symptoms are present, the patient should be evaluated
immediately. LAMICTAL should be discontinued if an alternative etiology
for the signs or symptoms cannot be established. Prior to initiation of treatment with
LAMICTAL, the patient should be instructed that a rash or other signs
or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may
herald a serious medical event and that the patient should report
any such occurrence to a physician immediately.<br/>Acute Multiorgan Failure: Multiorgan failure, which in some cases has been
fatal or irreversible, has been observed in patients receiving LAMICTAL.
Fatalities associated with multiorgan failure and various degrees
of hepatic failure have been reported in 2 of 3,796 adult patients
and 4 of 2,435 pediatric patients who received LAMICTAL in clinical
trials. No such fatalities have been reported in bipolar patients
in clinical trials. Rare fatalities from multiorgan failure have also
been reported in compassionate plea and postmarketing use. The majority
of these deaths occurred in association with other serious medical
events, including status epilepticus and overwhelming sepsis, and
hantavirus making it difficult to identify the initial cause. Additionally, 3 patients (a 45-year-old woman, a 3.5-year-old
boy, and an 11-year-old girl) developed multiorgan dysfunction and
disseminated intravascular coagulation 9 to 14 days after LAMICTAL
was added to their AED regimens. Rash and elevated transaminases were
also present in all patients and rhabdomyolysis was noted in 2 patients.
Both pediatric patients were receiving concomitant therapy with valproate,
while the adult patient was being treated with carbamazepine and clonazepam.
All patients subsequently recovered with supportive care after treatment
with LAMICTAL was discontinued.<br/>Blood Dyscrasias: There have been reports of blood dyscrasias that
may or may not be associated with the hypersensitivity syndrome. These
have included neutropenia, leukopenia, anemia, thrombocytopenia, pancytopenia,
and, rarely, aplastic anemia and pure red cell aplasia.<br/>Withdrawal Seizures: As with other AEDs, LAMICTAL should not be abruptly
discontinued. In patients with epilepsy there is a possibility of
increasing seizure frequency. In clinical trials in patients with
Bipolar Disorder, 2 patients experienced seizures shortly after
abrupt withdrawal of LAMICTAL. However, there were confounding factors
that may have contributed to the occurrence ofseizures in these bipolar
patients. Unless safety concerns require a more rapid withdrawal,
the dose of LAMICTAL should be tapered over a period of at least 2 weeks
(see DOSAGE AND ADMINISTRATION).
|
dailymed-instance:indicatio... |
Epilepsy:<br/>Adjunctive Use: LAMICTAL is indicated as adjunctive therapy for
partial seizures, the generalized seizures of Lennox-Gastaut syndrome,
and primary generalized tonic-clonic seizures in adults and pediatric
patients (���2 years of age).<br/>Monotherapy Use: LAMICTAL is indicated for conversion to monotherapy
in adults with partial seizures who are receiving treatment with carbamazepine,
phenytoin, phenobarbital, primidone, or valproate as the single AED. Safety and effectiveness of LAMICTAL have not been
established (1) as initial monotherapy, (2) for conversion to monotherapy
from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone,
or valproate, or (3) for simultaneous conversion to monotherapy from
2 or more concomitant AEDs (see DOSAGE AND ADMINISTRATION).<br/>Bipolar Disorder: LAMICTAL is indicated for the maintenance treatment
of Bipolar I Disorder to delay the time to occurrence of mood episodes
(depression, mania, hypomania, mixed episodes) in patients treated
for acute mood episodes with standard therapy. The effectiveness of
LAMICTAL in the acute treatment of mood episodes has not been established. The effectiveness of LAMICTAL as maintenance treatment
was established in 2 placebo-controlled trials of 18 months'
duration in patients with Bipolar I Disorder as defined by DSM-IV
(see CLINICAL STUDIES: Bipolar Disorder). The physician who elects
to use LAMICTAL for periods extending beyond 18 months should
periodically re-evaluate the long-termusefulness of the drug for
the individual patient.
|
dailymed-instance:represent... | |
dailymed-instance:routeOfAd... | |
dailymed-instance:name |
LAMICTAL
|